Target (CBDY) Cash from Investing Activities (2018 - 2026)
Target (CBDY) reported Cash from Investing Activities of -$40055.0 for Q1 2026, down 243.23% year-over-year from $27965.0 in Q1 2025, and down 407.59% quarter-over-quarter from $13022.0 in Q4 2025.
Target (CBDY) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Target (CBDY) has 9 years of Cash from Investing Activities data on file, last reported at -$40055.0 in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$40055.0, down 243.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $13359.0 (up 109.0% YoY), and the FY2025 annual result was $81379.0, up 145.47% from the prior year.
- Cash from Investing Activities fell to -$40055.0 in Q1 2026 per CBDY's latest filing, from $13022.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $1.3 million in Q2 2022 and troughed at -$538911.0 in Q1 2023.
- A 5-year average of $76136.4 and a median of $13022.0 in 2025 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities jumped 4211.69% in 2022, then slumped 289.6% in 2023.
- A 5-year view of Cash from Investing Activities shows it stood at -$225071.0 in 2022, then surged by 91.97% to -$18066.0 in 2023, then plunged by 177.28% to -$50094.0 in 2024, then surged by 126.0% to $13022.0 in 2025, then plunged by 407.59% to -$40055.0 in 2026.
- Business Quant data shows CBDY's Cash from Investing Activities at -$40055.0 in Q1 2026, $13022.0 in Q4 2025, and $24488.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 229.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | -87.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 743.70 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | -506.20 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | -60.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -2.08 Bn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 25.99 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -15.45 Mn |
| 10 | Target | - | - | 191,787.00 | -40,055.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40,055.00 |
| Mar 31, 2026 | -40,055.00 |
| Dec 31, 2025 | 13,022.00 |
| Dec 31, 2025 | 13,022.00 |
| Sep 30, 2025 | 24,488.00 |
| Sep 30, 2025 | 24,488.00 |
| Jun 30, 2025 | 15,904.00 |
| Jun 30, 2025 | 15,904.00 |
| Mar 31, 2025 | 27,965.00 |
| Mar 31, 2025 | 27,965.00 |
| Dec 31, 2024 | -50,094.00 |
| Dec 31, 2024 | -50,094.00 |
| Sep 30, 2024 | -142,743.00 |
| Sep 30, 2024 | -142,743.00 |
| Jun 30, 2024 | 16,376.00 |
| Jun 30, 2024 | 16,376.00 |
| Mar 31, 2024 | -2,517.00 |
| Mar 31, 2024 | -2,517.00 |
| Dec 31, 2023 | -18,066.00 |
| Dec 31, 2023 | -18,066.00 |